drugset / Trial / NCT01118975
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
Phase 1/2
Terminated
12 enrolled
University of Maryland, Baltimore
University of Maryland Greenebaum Cancer Center · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This research is being done to find out how safe and how well the combination of lapatinib and vorinostat works against advanced cancers.
Timeline
- Start
- 2010-03
- Primary completion
- 2012-10
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | 1250 mg | — |
| Subject | Vorinostat | Small molecule | 300 mg | — |
| Subject | Vorinostat | Small molecule | 400 mg | — |